Transformative Therapeutics
Our Cutting-Edge Assets
Our pipeline aims to disrupt existing treatment paradigm and features new molecular entities that inhibit novel targets with first–in–class potential for autoimmune, inflammatory, and other debilitating diseases.
Program
FRTX-02
Oral DYRK1A Inhibitor
Discovery
Preclinical
Phase 1
Phase 2
Phase 3
Autoimmune Diseases:
Atopic Dermatitis | Rheumatoid Arthritis | Type 1 Diabetes | Others
Next Milestone:
Phase 1 SAD/MAD Topline Results: Early 2023
Program
FRTX-10
Oral STING Inhibitor
Discovery
Preclinical
Phase 1
Phase 2
Phase 3
Autoinflammatory Diseases:
Systemic Lupus Erythematosus | NASH | Dermatomyositis
Next Milestone:
Preclinical Development
Program
Next-Generation Kinase Inhibitors
Oral DYRK1A, LRRK2, TTK, and CLK Inhibitors
Discovery
Preclinical
Phase 1
Phase 2
Phase 3
Autoimmune, Neuroinflammatory, and Other Diseases
Next Milestone:
Experimental Characterization
Program
FRTX-03
Topical DYRK1A Inhibitor
Discovery
Preclinical
Phase 1
Phase 2
Phase 3